Lundbeck's Northera took massive dive in 2021
The patent expiration of Northera last year has cost Lundbeck almost DKK 2bn (USD 307.3m).
by marketwire, translated by daniel pedersen
Key figures in Lundbeck’s fourth quarterly disappointed, and as a consequence, the company’s full-year 2021 report was below expectations.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck's migraine drug approved in EU
For subscribers
